If you work in any sector of the life sciences industry, you know how important it is to comply with 21 CFR Part 11, the part of Title 21 of the Code of Federal Regulations that sets the standards for ensuring the authenticity, integrity, and reliability of electronic records and signatures (ERES) used or submitted to the FDA. The regulation, also referred to as simply Part 11, applies to pharmaceutical companies, medical device manufacturers, biotech companies, biologics developers, contract research organizations (CROs), and other FDA-regulated companies.
Given its widespread reach, understanding the intent, requirements, and challenges of 21 CFR Part 11 compliance is essential knowledge for all life sciences professionals and the focus of this blog post.
21 CFR Part 11 provides the criteria for acceptance by the FDA of electronic records, electronic signatures, and handwritten signatures executed to electronic records as equivalent to paper records and handwritten signatures executed on paper. Simply put, 21 CFR Part 11 outlines the standards that electronic records and signatures must meet in order to be deemed reliable and equivalent to their paper counterparts.
The regulatory origins of 21 CFR Part 11 date back to 1997, a time when the industry was increasing its use of computer systems. The intent was to define controls for computer systems and encourage the use of electronic technology, all while upholding the FDA's commitment to safeguarding public health.
The regulation has three main parts: Subpart A covers the general provisions, such as the scope, definitions, and implementation of the regulation. Subpart B covers the requirements for electronic records, such as the controls for closed and open systems, the signature manifestations, and the signature/record linking. Subpart C covers the requirements for electronic signatures, such as the general requirements, the components and controls, and the identification codes/passwords.
21 CFR Part 11 also provides guidance on how to comply with the regulation in different situations, such as validation, audit trail, legacy systems, copies of records, and record retention. The guidance document, published in 2003, explains the FDA’s current thinking and interpretation of the regulation.
Let's explore 21 CFR Part 11 compliance in the context of validation.
If your products are subject to regulatory requirements, you must validate your electronic systems in accordance with 21 CFR Part 11. While the FDA mandates computer system validation, it does not prescribe a specific method. Instead, the agency seeks evidence that you have documented your validation intentions and have executed them as specified. The main goal is to guarantee that the software functions as intended and can detect any compromised or modified records easily.
But how do you manage your validation activities in a compliant way? How do you ensure that your electronic records and signatures are secure, accurate, and traceable? How do you avoid the hassle of paper-based validation documents that are prone to errors and delays?
The ValGenesis validation lifecycle management system (VLMS) was designed for 21 CFR Part 11 compliance in the pharmaceutical industry and other sectors of the life sciences. Users can create, review, approve, and execute validation documents electronically and manage the entire validation lifecycle in a 100% paperless, compliant way.
Here are some of the features and benefits of the ValGenesis VLMS that demonstrate 21 CFR Part 11 compliance:
ValGenesis VLMS is a powerful and flexible solution that can help you achieve your 21 CFR Part 11 compliance goals. By using ValGenesis VLMS, you can: